Article thumbnail

Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia

By Joseph T. Coyle, Darrick Balu, Michael Benneyworth, Alo Basu and Alexander Roseman


All current drugs approved to treat schizophrenia appear to exert their antipsychotic effects through blocking the dopamine D2 receptor. Recent meta-analyses and comparative efficacy studies indicate marginal differences in efficacy of newer atypical antipsychotics and the older drugs, and little effects on negative and cognitive symptoms. This review integrates findings from postmortem, imaging, and drug-challenge studies to elucidate a corticolimbic “pathologic circuit” in schizophrenia that may be particularly relevant to the negative symptoms and cognitive impairments of schizophrenia. Potential sites for pharmacologic intervention targeting glutatatergic, GABAergic, and cholinergic neurotransmission to treat these symptoms of schizophrenia are discussed

Topics: Pharmacological Aspects
Publisher: Les Laboratoires Servier
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but not mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus.
  2. (2007). A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia. Schizophr Res.
  3. A genetic variant of the serine racemase gene is associated with schizophrenia. Biol Psychiatry.
  4. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry.
  5. A meta-analysis of the efficacy of secondgeneration antipsychotics.
  6. A schizophrenia-related sensorimotor deficit links alpha 3-containing GABAA receptors to a dopamine hyperfunction.
  7. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity.
  8. A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis.
  9. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.
  10. Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats.
  11. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus.
  12. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci.
  13. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
  14. Acute but not chronic activation of the NMDA-coupled glycine receptor with Dcycloserine facilitates learning and retention.
  15. Adjunctive high-dose glycine in the treatment of schizophrenia.
  16. ADX47273 [S-(4-fluorophenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities.
  17. Aghajanian GK Physiological antagonism between 5-hydroxytryptamine 2A and group II metabotropic glutamate receptors in prefrontal corotex.
  18. (2008). Allelic association of G72/ G30 with schizophrenia and bipolar disorder: a comprehensive meta-analysis. Schizophr Res.
  19. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia. Pharmacol Ther.
  20. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov.
  21. (2009). Altered cortical dendritic morphology in serine racemase knockout mice, a genetic model of NMDA receptor hypofunction. Soc Neurosci.
  22. (1993). Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry.
  23. (2009). Altered functional and anatomical connectivity in schizophrenia. Schizophr Bull.
  24. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia.
  25. An analysis of factors influencing measurements of dopamine, noradrenaline, glutamate decarboxylase and choline acetylase in human post-mortem brain tissue.
  26. (1976). Antipsychotic drug doses and neuroleptic/dopamine receptors.
  27. Awouters FH. Is it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to risperidone.
  28. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice.
  29. (2006). Bursting of prefrontal cortex neurons in awake rats is regulated by metabotropic glutamate 5 (mGlu5) receptors: rate-dependent influence and interaction with NMDA receptors. Cereb Cortex.
  30. Cerebral cystine uptake: a tale of two transporters. Trends Pharmacol Sci.
  31. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci.
  32. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
  33. (1992). Cloning, expression, and localization of a rat brain high-affinity glycine transporter.
  34. Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizocilpine.
  35. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations.
  36. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear.
  37. Comparative effectiveness of antipsychotic drugs: a commentary on: Cost Utility Of The Latest Antipsychotic Drugs In
  38. Comparison of the mGlu receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity.
  39. Conserved regional patterns of GABA-related transcript expression in the neocortex of subjects with schizophrenia.
  40. Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine.
  41. (2009). Convergent approaches for defining functional imaging endophenotypes in schizophrenia. Front Hum Neurosci.
  42. Cooperative modulation of [3H]MK-801 binding to the N-methyl-D-aspartate receptor-ion channel complex by L-glutamate, glycine, and polyamines.
  43. Cortical inhibitory neurons and schizophrenia.
  44. Corticolimbic dopamine neurotransmission is temporally dissociated from the cognitive and locomotor effects of phencyclidine.
  45. Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins.
  46. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking.
  47. D-amino acid oxidase activity and expression are increased in schizophrenia. Mol Psychiatry.
  48. (1990). D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res.
  49. D-cycloserine facilitates extinction of naloxone-induced conditioned place aversion in morphine-dependent rats. Biol Psychiatry.
  50. Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry.
  51. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the Nmethyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.
  52. Differential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate- and electrically evoked responses in the pryramidal cells of the rat medial prefrontal cortex.
  53. Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus.
  54. Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine.
  55. Distribution and pharmacology of alanine-serine-cysteine transporter 1 (asc-1) in rodent brain.
  56. (1977). Does dopamine play a role in schizophrenia? Psychol Med.
  57. (1998). Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities? Neuropsychopharmacology
  58. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs.
  59. (2010). Dopamine system dysregulation by the ventral subiculum as the common pathophysiological basis for schizophrenia psychosis, psychostimulant abuse, and stress. Neurotox Res.
  60. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia.
  61. Dysbindin modulates prefrontal cortical glutamatergic circuits and working memory function in mice.
  62. (1967). Effect of phencyclidine in chronic schizophrenics. Can Psychiatr Assoc J.
  63. Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease. Curr Med Res Opin.
  64. Effect of systemic administration of D-serine on the levels of D- and L-serine in several brain areas and periphery of rat.
  65. (1999). Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry.
  66. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res.
  67. (1999). Evidence for altered trisynaptic circuitry in schizophrenic hippocampus. Biol Psychiatry.
  68. Evidence from gene knockout studies implicates Asc-1 as the primary transporter mediating d-serine reuptake in the mouse CNS.
  69. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of Dcycloserine as assessed with fear-potentiated startle in rats.
  70. (1995). Functional comparison of D-serine and glycine in rodents: the effect on cloned NMDA receptors and the extracellular concentration.
  71. Functional interaction Between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release.
  72. G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis. Biol Psychiatry.
  73. Genetic and physiological data implicating the new human gene G72 and the gene for Damino acid oxidase in schizophrenia.
  74. Glutamate and schizophrenia: beyond the dopamine hypothesis.
  75. Glycine enhances NMDA-receptor mediated synaptic potentials in neocortical slices.
  76. Glycine potentiates the NMDA response in cultured mouse brain neurons.
  77. Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo.
  78. (1998). Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses.
  79. High affinity D- and L-serine transporter Asc-1: cloning and dendritic localization in the rat cerebral and cerebellar cortices.
  80. (2006). Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultrahigh-risk individuals. Arch Gen Psychiatry.
  81. Hyperactivity and hyperconnectivity of the default network in schizophrenia and in firstdegree relatives of persons with schizophrenia.
  82. Identification of GABAA receptor subunit variants in midbrain dopaminergic neurons.
  83. Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden.
  84. In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties.
  85. Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia. Schizophr Res.
  86. (2001). Increased cortical kynurenate content in schizophrenia. Biol Psychiatry.
  87. (2005). Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Mol Psychiatry.
  88. Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia.
  89. (1998). International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev.
  90. Interneuron diversity series: inhibitory interneurons and network oscillations in vitro. Trends Neurosci.
  91. Involvement of D-amino acid oxidase in elimination of Dserine in mouse brain.
  92. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry.
  93. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase.
  94. (1999). Ketamineinduced NMDA receptor hypofunction as a model of memory impairment and psychosis.
  95. Lack of the alanine-serine-cysteine transporter 1 causes tremors, seizures, and early postnatal death in mice. Brain Res.
  96. Localization of D-amino acid oxidase in Bergmann glial cells and astrocytes of rat cerebellum.
  97. Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s).
  98. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons.
  99. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharm Ther.
  100. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov.
  101. Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents.
  102. (2000). Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry.
  103. (1998). Modulation of N-methylD-aspartate receptor function by glycine transport.
  104. (1993). Modulation of neuronal migration by NMDA receptors.
  105. Mohler H GABA-based therapeutic approaches: GABAA receptor subtype functions.
  106. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Ther.
  107. (2008). N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. Biol Psychiatry.
  108. N-acetyl cysteine-induced blockade of cocaine-induced reinstatement.
  109. N-acetylcysteine reduces extinction responding and induces enduring reductions in cue- and heroin-induced drug-seeking. Biol Psychiatry.
  110. Network analysis of positional candidate genes of schizophrenia highlights myelin-related pathways. Mol Psychiatry.
  111. Neurocognition in first-episode schizophrenia: a meta-analytic review.
  112. (1998). Neurocognitive deficit in schizophrenia: a quantitative review of the evidence.
  113. Neuroleptic effects of chlorpromazine in therapeutics of neuropsychiatry.
  114. Neuronal signaling pathways: genetic insights into the pathophysiology of major mental illness.
  115. Neuronderived D-serine release provides a novel means to activate N-methyl-Daspartate receptors.
  116. NMDA receptor channels: subunit-specific potentiation by reducing agents.
  117. (2001). NMDA receptor pharmacology: Perspectives from molecular biology. Curr. Drug Targets.
  118. Penrose's law revisited: the relationship between mental institution beds, prison population and crime rate.
  119. Pharmacological agents acting at subtypes of metabotropic glutamate receptors.
  120. Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol Pharmacol.
  121. Pharmacological characterization of stress-induced hyperthermia in DBA/2 mice using metabotropic and ionotropic glutamate receptor ligands.
  122. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol.
  123. Phencyclidine-induced impairment in attention and response control depends on the background genotype of mice: reversal by the mGLU(2/3) receptor agonist LY379268. Psychopharmacology (Berl).
  124. (2006). Polymorphism in the 5'-promoter region of serine racemase gene in schizophrenia. Mol Psychiatry.
  125. Preliminary evidence for a link between schizophrenia and NMDA-glycine site receptor ligand metabolic enzymes, d-amino acid oxidase (DAAO) and kynurenine aminotransferase-1 (KAT-1). Brain Res.
  126. Presynaptic group II metabotropic glutamate receptors reduce stimulated and spontaneous transmitter release in human dentate gyrus.
  127. (1993). Prevalence of alcohol, drug and mental disorders among the homeless: one more time. Contemporary Drug Problems.
  128. (2006). Progress in the preparation and testing of glycine transporter type-1 (GlyT1) inhibitors. Curr Top Med Chem.
  129. (2007). Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. Arch Gen Psychiatry.
  130. Prolonged exposure to NMDAR antagonist suppresses inhibitory synaptic transmission in prefrontal cortex.
  131. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia:
  132. (1991). Recent advances in the phencyclidine model of schizophrenia.
  133. Recent diffusion tensor imaging findings in early stages of schizophrenia. Curr Opin Psychiatry.
  134. Reciprocal alterations in pre- and post-synaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb Cortex.
  135. Reduced dendritic spine density in auditory cortex of subjects with schizophrenia.
  136. (1995). Regional distribution and developmental variation of the glycine transporters
  137. Regulation of neurotransmitter release by metabotropic glutamate receptors.
  138. Regulation of spine morphology and spine density by NMDA receptor signaling in vivo.
  139. (1992). Relationship between symptoms rated with the Positive and Negative Syndrome Scale and brain measures in schizophrenia. Psychiatry Res.
  140. Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes.
  141. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats.
  142. Role of GABAA receptors in cognition. Biochem Soc Trans.
  143. Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity.
  144. Sejnowksi TJ Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex?
  145. Selective alterations in postsynaptic markers of chandelier cell inputs to cortical pyramidal neurons in subjects with schizophrenia.
  146. Sensory processing in schizophrenia: neither simple nor intact.
  147. Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model. Hum Mol Genet.
  148. Serine racemase is predominantly localized in neurons in mouse brain.
  149. Shigemoto R Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites.
  150. Splice variants of the NR1 subunit differentially induce NMDA receptor-dependent gene expression.
  151. Strategies to enhance N-methyl-D-aspartate receptormediated neurotransmission in schizophrenia, a critical review and metaanalysis. Curr Pharm Des.
  152. Study of a new schizophrenomimetic drug; sernyl.
  153. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry
  154. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia.
  155. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database.
  156. Tamminga CA. Effects of ketamine in normal and schizophrenic volunteers.
  157. Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior. Mol Psychiatry.
  158. The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist.
  159. The behavioral and neurochemical effects of a novel D-amino acid oxidase inhibitor compound 8 [4H-thieno [3,2-b]pyrrole-5-carboxylic acid] and D-serine.
  160. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
  161. (2010). The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms.
  162. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate.
  163. (2002). The economic burden of schizophrenia in the United States in
  164. The glutamate homeostasis hypothesis of addiction.
  165. The glycine transporter type 1 inhibitor N-[3-(4_-fluorophenyl)-3-(4_- phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior.
  166. The group II metabotropic glutamate receptor agonist, LY379268, inhibits both cocaine- and food-seeking behavior in rats.
  167. (1999). The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J Pharmacol Exp Ther.
  168. The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats.
  169. The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity.
  170. The neurobiology of Damino acid oxidase and its involvement in schizophrenia. Mol Psychiatry.
  171. (1996). The NMDA antagonist MK-801 blocks the extinction of Pavlovian fear conditioning. Behav Neurosci.
  172. The novel anticonvulsant MK-801 binds to the activated state of the N-methyl-D-aspartate receptor in rat brain.
  173. (2007). The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/neuroprotection.
  174. (1971). Uptake of radiolabeled essential amino acids by brain following arterial injection. Proc Soc Exp Biol Med.
  175. Use-dependent increases in glutamate concentration activate presynaptic metabotropic glutamate receptors.